Work

Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma

Year: 2016

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-016-3056-0

Authors: Oliver E. Bechter, Herlinde Dumez, Jo Costermans, Kevin Punie, Karl Hsu, Jean-François Dedieu, Anne-Frédérique Ghuysen, Elisa Francesconi, Jyoti Sharma, Li Liu, Patrick Schöffski

Institutions: Universitair Ziekenhuis Leuven, KU Leuven, Sanofi (France), Sanofi (United States)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Sanofi

OpenAlex ID: W2362827599

FWCI: 0.173

Cites: 35

Cited by: 6

Related to: 10